RecruitingNCT06726590
Interprofessional Pharmacogenomics (IPGx) Registry and Repository
The Texas Interprofessional Pharmacogenomics Registry and Repository
Sponsor
Texas A&M University
Enrollment
3,000 participants
Start Date
Nov 1, 2025
Study Type
OBSERVATIONAL
Conditions
Summary
This program collects genetic and health information to help doctors choose the right medications for patients.
Eligibility
Min Age: 18 Years
Inclusion Criteria8
- The study will invite patients who are eligible for PGX workup/PGX care to participate, provided they meet the following criteria: Use of five or more medications, including over the counter drugs, supplements, natural products, cannabis products, or other recreational drugs, or
- Individuals taking blood pressure or depression medications, even if less than five medications.
- Ability to understand and give consent.
- Able to consent to donate blood and/or urine samples and buccal swabs.
- Able to answer detailed questionnaires, including quarterly questionnaires about ADRs, cognitive testing such as serial mini-mental status exams, and or quality of life questions.
- Able to understand that their health record and changes in health status will be followed for a five-year period and shared in deidentified form with the research community.
- All genders.
- Any age over 18 years.
Exclusion Criteria5
- Individuals admitted to hospice.
- Declines to participate or interact with staff/share their medical status.
- A diagnosis of Alzheimer's disease or related dementias in a medical record as this indicates a progressive, debilitating condition that impairs memory, thought processes, and functioning.,
- Individuals who are unable or unwilling to provide consent.
- Unable to verbally communicate and comprehend English language
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06726590
Related Trials
A Study to Learn About Study Medicine ALTA3263 in Adults With Advanced Solid Tumors With KRAS Mutations
NCT068355699 locations
A Dose Finding Phase 1 of Sarilumab Plus Capecitabine in HER2/Neu-Negative Metastatic Breast Cancer and a Single-arm, Historically-controlled Phase 2 Study of Sarilumab Plus Capecitabine in Stage I-III Triple Negative Breast Cancer With High-Risk Residual Disease (EMPOWER)
NCT043337063 locations
A Study to Learn About Study Medicine ALTA2618 in Adults With AKT1 E17K-Mutant Solid Tumors
NCT0653305951 locations
Psilocybin-Assisted Psychotherapy in Cancer Patients With Adjustment Disorder
NCT070727283 locations
Leveraging Lung Cancer Screening to Optimize Screening Outcomes and COPD Management: COPD in LCS Registry
NCT069749811 location